Menu
Search
|

Menu

Close
X

Celgene Corp CELG.OQ (NASDAQ Stock Exchange Global Select Market)

98.60 USD
+0.22 (+0.22%)
As of 4:00 PM EDT
Previous Close 98.38
Open 98.26
Volume 1,058,997
3m Avg Volume 1,294,497
Today’s High 98.98
Today’s Low 98.26
52 Week High 99.36
52 Week Low 58.61
Shares Outstanding (mil) 705.26
Market Capitalization (mil) 65,582.09
Forward P/E 14.27
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.85 Mean rating from 20 analysts

KEY STATS

Revenue (mm, USD)
FY19
4,025
FY18
15,281
FY17
13,000
FY16
11,229
EPS (USD)
FY19
2.144
FY18
5.473
FY17
5.204
FY16
2.486
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
14.27
33.85
Price to Sales (TTM)
vs sector
4.16
7.90
Price to Book (MRQ)
vs sector
8.03
4.38
Price to Cash Flow (TTM)
vs sector
12.22
23.70
Total Debt to Equity (MRQ)
vs sector
248.39
17.64
LT Debt to Equity (MRQ)
vs sector
242.27
12.61
Return on Investment (TTM)
vs sector
14.44
12.69
Return on Equity (TTM)
vs sector
70.51
17.13

EXECUTIVE LEADERSHIP

Mark Alles
Chairman of the Board, Chief Executive Officer, Since 2018
Salary: $1,266,670.00
Bonus: $2,144,620.00
Alise Reicin
President - Global Clinical Development, Since 2018
Salary: --
Bonus: --
David Elkins
Chief Financial Officer, Executive Vice President, Since 2018
Salary: --
Bonus: --
Terrie Curran
President, Global Inflammation & Immunology Franchise, Since 2017
Salary: --
Bonus: --
Rupert Vessey
President - Research and Early Development, Since 2016
Salary: $691,917.00
Bonus: $957,442.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

86 Morris Ave
SUMMIT   NJ   07901-3915

Phone: +1908.6739000

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

SPONSORED STORIES